### Table 3 Subgroup analysis for BNP

| Variables | Participants(n) | MD [95% CI]                        | P value (Significance tests) |
|-----------|-----------------|------------------------------------|------------------------------|
| MODEL of CHF |                 |                                    |                              |
| drug(DOX) | 56              | -4.528 [-18.408, 9.352]            | 0.523                        |
| surgery(AAC) | 88            | -57.419 [-88.458, -26.381]        | 0.000                        |
| surgery(TAC) | 57            | -807.696 [-1.4e+03, -171.678]      | 0.013                        |
| surgery(LAD) | 19            | -96.800 [-128.677, -64.923]       | 0.000                        |
| Duration   |                 |                                    |                              |
| <21days    | 57              | -807.696 [-1.4e+03, -171.678]      | 0.013                        |
| ≥21days    | 163             | -41.656 [-67.957, -15.354]         | 0.002                        |

### Table 4 Subgroup analysis according to HR

| Variables | Participants(n) | MD [95% CI]                        | P value (Significance tests) |
|-----------|-----------------|------------------------------------|------------------------------|
| MODEL of CHF |                 |                                    |                              |
| drug(DOX) | 138             | 32.739 [6.400, 59.078]             | 0.015                        |
| surgery(AAC) | 70            | 7.427 [-9.454, 24.309]             | 0.388                        |
| Duration   |                 |                                    |                              |
| <21days    | 138             | 32.739 [6.400, 59.078]             | 0.015                        |
| ≥21days    | 70              | 7.427 [-9.454, 24.309]             | 0.388                        |

### Table 5 Subgroup analysis according to HWI

| Variables | Participants(n) | MD [95% CI]                        | P value (Significance tests) |
|-----------|-----------------|------------------------------------|------------------------------|
| MODEL of CHF |                 |                                    |                              |
| drug(DOX) | 57              | -0.079 [-0.237, 0.078]             | 0.323                        |
| surgery(AAC) | 70            | -0.072 [-0.177, 0.034]             | 0.185                        |
| surgery(TAC) | 13            | -0.120 [-0.138, -0.102]            | 0.000                        |
| Duration   |                 |                                    |                              |
| <21days    | 13              | -0.120 [-0.138, -0.102]            | 0.000                        |
| ≥21days    | 127             | -0.078 [-0.155, -0.002]            | 0.045                        |

### Table 6 Subgroup analysis according to ALD

| Variables | Participants(n) | MD [95% CI]                        | P value (Significance tests) |
|-----------|-----------------|------------------------------------|------------------------------|
| MODEL of CHF^ |               |                                    |                              |
| drug(DOX) | 48              | -168.021 [-260.951, -75.092]       | 0.000                        |
| surgery(AAC) | 70            | -1.039 [-3.677, 1.598]             | 0.440                        |

^: source of significant heterogeneity.